nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—FGFR2—Pazopanib—kidney cancer	0.184	0.48	CbGbCtD
Thalidomide—PTGS1—kidney cancer	0.129	0.402	CbGaD
Thalidomide—CYP1A1—kidney cancer	0.118	0.368	CbGaD
Thalidomide—FGFR2—Sunitinib—kidney cancer	0.0866	0.226	CbGbCtD
Thalidomide—PTGS2—kidney cancer	0.074	0.23	CbGaD
Thalidomide—CYP3A5—Temsirolimus—kidney cancer	0.022	0.0574	CbGbCtD
Thalidomide—CYP1A1—Erlotinib—kidney cancer	0.0138	0.0358	CbGbCtD
Thalidomide—CYP1A2—Pazopanib—kidney cancer	0.00861	0.0224	CbGbCtD
Thalidomide—CYP3A5—Erlotinib—kidney cancer	0.00826	0.0215	CbGbCtD
Thalidomide—CYP2C9—Capecitabine—kidney cancer	0.00809	0.0211	CbGbCtD
Thalidomide—CYP3A5—Paclitaxel—kidney cancer	0.00756	0.0197	CbGbCtD
Thalidomide—CYP3A5—Sorafenib—kidney cancer	0.00671	0.0175	CbGbCtD
Thalidomide—CYP3A5—Vincristine—kidney cancer	0.00652	0.017	CbGbCtD
Thalidomide—CYP1A2—Erlotinib—kidney cancer	0.00615	0.016	CbGbCtD
Thalidomide—CYP3A5—Sunitinib—kidney cancer	0.00544	0.0142	CbGbCtD
Thalidomide—CYP2C19—Sorafenib—kidney cancer	0.00542	0.0141	CbGbCtD
Thalidomide—CYP2C9—Paclitaxel—kidney cancer	0.00507	0.0132	CbGbCtD
Thalidomide—CYP1A2—Sorafenib—kidney cancer	0.005	0.013	CbGbCtD
Thalidomide—CYP2C9—Sorafenib—kidney cancer	0.0045	0.0117	CbGbCtD
Thalidomide—CYP2C19—urine—kidney cancer	0.00194	0.0682	CbGeAlD
Thalidomide—PTGS2—nephron—kidney cancer	0.00164	0.0575	CbGeAlD
Thalidomide—CYP1A2—urine—kidney cancer	0.00159	0.0557	CbGeAlD
Thalidomide—CYP2C9—urine—kidney cancer	0.0015	0.0529	CbGeAlD
Thalidomide—CYP2E1—urine—kidney cancer	0.00143	0.0501	CbGeAlD
Thalidomide—NFKB1—renal system—kidney cancer	0.00141	0.0494	CbGeAlD
Thalidomide—NFKB1—kidney—kidney cancer	0.00136	0.0478	CbGeAlD
Thalidomide—NFKB1—cortex of kidney—kidney cancer	0.00133	0.0465	CbGeAlD
Thalidomide—CRBN—nephron tubule—kidney cancer	0.0013	0.0456	CbGeAlD
Thalidomide—NFKB1—gonad—kidney cancer	0.00126	0.0443	CbGeAlD
Thalidomide—NFKB1—cardiac atrium—kidney cancer	0.00126	0.0443	CbGeAlD
Thalidomide—CRBN—renal system—kidney cancer	0.00118	0.0414	CbGeAlD
Thalidomide—CRBN—cortex of kidney—kidney cancer	0.00111	0.039	CbGeAlD
Thalidomide—CRBN—gonad—kidney cancer	0.00106	0.0372	CbGeAlD
Thalidomide—FGFR2—renal system—kidney cancer	0.00106	0.0371	CbGeAlD
Thalidomide—CRBN—cardiac atrium—kidney cancer	0.00106	0.0371	CbGeAlD
Thalidomide—FGFR2—kidney—kidney cancer	0.00102	0.0359	CbGeAlD
Thalidomide—Lenalidomide—PTGS2—kidney cancer	0.000525	0.235	CrCbGaD
Thalidomide—Pomalidomide—PTGS2—kidney cancer	0.000488	0.219	CrCbGaD
Thalidomide—Lenalidomide—ABCB1—kidney cancer	0.000446	0.2	CrCbGaD
Thalidomide—Pomalidomide—ABCB1—kidney cancer	0.000415	0.186	CrCbGaD
Thalidomide—CYP3A5—nephron tubule—kidney cancer	0.000412	0.0145	CbGeAlD
Thalidomide—CYP1A2—renal system—kidney cancer	0.000388	0.0136	CbGeAlD
Thalidomide—CYP2E1—nephron tubule—kidney cancer	0.000384	0.0135	CbGeAlD
Thalidomide—CYP1A1—renal system—kidney cancer	0.000383	0.0134	CbGeAlD
Thalidomide—CYP3A5—renal system—kidney cancer	0.000374	0.0131	CbGeAlD
Thalidomide—CYP1A1—kidney—kidney cancer	0.00037	0.013	CbGeAlD
Thalidomide—CYP3A5—kidney—kidney cancer	0.000362	0.0127	CbGeAlD
Thalidomide—Menadione—CYP1A1—kidney cancer	0.000359	0.161	CrCbGaD
Thalidomide—CYP3A5—cortex of kidney—kidney cancer	0.000352	0.0124	CbGeAlD
Thalidomide—CYP2E1—renal system—kidney cancer	0.000349	0.0123	CbGeAlD
Thalidomide—CYP1A1—cardiac atrium—kidney cancer	0.000343	0.012	CbGeAlD
Thalidomide—CYP2E1—kidney—kidney cancer	0.000337	0.0118	CbGeAlD
Thalidomide—PTGS1—renal system—kidney cancer	0.000336	0.0118	CbGeAlD
Thalidomide—CYP2E1—cortex of kidney—kidney cancer	0.000329	0.0115	CbGeAlD
Thalidomide—PTGS1—kidney—kidney cancer	0.000325	0.0114	CbGeAlD
Thalidomide—PTGS2—renal system—kidney cancer	0.000321	0.0113	CbGeAlD
Thalidomide—PTGS2—kidney—kidney cancer	0.000311	0.0109	CbGeAlD
Thalidomide—PTGS1—cardiac atrium—kidney cancer	0.000301	0.0106	CbGeAlD
Thalidomide—Liver function test abnormal—Doxorubicin—kidney cancer	2.8e-05	0.000168	CcSEcCtD
Thalidomide—Infection—Paclitaxel—kidney cancer	2.8e-05	0.000168	CcSEcCtD
Thalidomide—Flatulence—Capecitabine—kidney cancer	2.8e-05	0.000168	CcSEcCtD
Thalidomide—Dry skin—Doxorubicin—kidney cancer	2.78e-05	0.000167	CcSEcCtD
Thalidomide—Dysgeusia—Capecitabine—kidney cancer	2.78e-05	0.000167	CcSEcCtD
Thalidomide—Dizziness—Sunitinib—kidney cancer	2.78e-05	0.000166	CcSEcCtD
Thalidomide—Feeling abnormal—Gemcitabine—kidney cancer	2.78e-05	0.000166	CcSEcCtD
Thalidomide—Shock—Paclitaxel—kidney cancer	2.78e-05	0.000166	CcSEcCtD
Thalidomide—Vomiting—Sorafenib—kidney cancer	2.77e-05	0.000166	CcSEcCtD
Thalidomide—Orthostatic hypotension—Doxorubicin—kidney cancer	2.77e-05	0.000166	CcSEcCtD
Thalidomide—Nervous system disorder—Paclitaxel—kidney cancer	2.77e-05	0.000166	CcSEcCtD
Thalidomide—Hypokalaemia—Doxorubicin—kidney cancer	2.76e-05	0.000166	CcSEcCtD
Thalidomide—Thrombocytopenia—Paclitaxel—kidney cancer	2.76e-05	0.000166	CcSEcCtD
Thalidomide—Tachycardia—Paclitaxel—kidney cancer	2.75e-05	0.000165	CcSEcCtD
Thalidomide—Rash—Sorafenib—kidney cancer	2.75e-05	0.000165	CcSEcCtD
Thalidomide—Dermatitis—Sorafenib—kidney cancer	2.75e-05	0.000165	CcSEcCtD
Thalidomide—Back pain—Capecitabine—kidney cancer	2.74e-05	0.000164	CcSEcCtD
Thalidomide—Breast disorder—Doxorubicin—kidney cancer	2.74e-05	0.000164	CcSEcCtD
Thalidomide—Skin disorder—Paclitaxel—kidney cancer	2.74e-05	0.000164	CcSEcCtD
Thalidomide—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	2.73e-05	0.000164	CcSEcCtD
Thalidomide—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	2.73e-05	0.000164	CcSEcCtD
Thalidomide—Headache—Sorafenib—kidney cancer	2.73e-05	0.000164	CcSEcCtD
Thalidomide—Muscle spasms—Capecitabine—kidney cancer	2.73e-05	0.000163	CcSEcCtD
Thalidomide—Hyperhidrosis—Paclitaxel—kidney cancer	2.73e-05	0.000163	CcSEcCtD
Thalidomide—Diarrhoea—Dactinomycin—kidney cancer	2.72e-05	0.000163	CcSEcCtD
Thalidomide—Anorexia—Paclitaxel—kidney cancer	2.69e-05	0.000161	CcSEcCtD
Thalidomide—Alanine aminotransferase increased—Doxorubicin—kidney cancer	2.68e-05	0.000161	CcSEcCtD
Thalidomide—Muscular weakness—Doxorubicin—kidney cancer	2.68e-05	0.000161	CcSEcCtD
Thalidomide—Vision blurred—Capecitabine—kidney cancer	2.67e-05	0.00016	CcSEcCtD
Thalidomide—Vomiting—Sunitinib—kidney cancer	2.67e-05	0.00016	CcSEcCtD
Thalidomide—Body temperature increased—Gemcitabine—kidney cancer	2.66e-05	0.00016	CcSEcCtD
Thalidomide—Tremor—Capecitabine—kidney cancer	2.66e-05	0.000159	CcSEcCtD
Thalidomide—Rash—Sunitinib—kidney cancer	2.65e-05	0.000159	CcSEcCtD
Thalidomide—Dermatitis—Sunitinib—kidney cancer	2.65e-05	0.000159	CcSEcCtD
Thalidomide—Abdominal distension—Doxorubicin—kidney cancer	2.64e-05	0.000158	CcSEcCtD
Thalidomide—Hypotension—Paclitaxel—kidney cancer	2.64e-05	0.000158	CcSEcCtD
Thalidomide—Ill-defined disorder—Capecitabine—kidney cancer	2.63e-05	0.000158	CcSEcCtD
Thalidomide—Headache—Sunitinib—kidney cancer	2.63e-05	0.000158	CcSEcCtD
Thalidomide—Influenza—Doxorubicin—kidney cancer	2.62e-05	0.000157	CcSEcCtD
Thalidomide—Dysphagia—Doxorubicin—kidney cancer	2.62e-05	0.000157	CcSEcCtD
Thalidomide—Anaemia—Capecitabine—kidney cancer	2.62e-05	0.000157	CcSEcCtD
Thalidomide—Hypersensitivity—Vincristine—kidney cancer	2.62e-05	0.000157	CcSEcCtD
Thalidomide—Eosinophilia—Doxorubicin—kidney cancer	2.6e-05	0.000156	CcSEcCtD
Thalidomide—Nausea—Sorafenib—kidney cancer	2.59e-05	0.000155	CcSEcCtD
Thalidomide—Pancreatitis—Doxorubicin—kidney cancer	2.57e-05	0.000154	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Paclitaxel—kidney cancer	2.57e-05	0.000154	CcSEcCtD
Thalidomide—Malaise—Capecitabine—kidney cancer	2.56e-05	0.000153	CcSEcCtD
Thalidomide—Angina pectoris—Doxorubicin—kidney cancer	2.56e-05	0.000153	CcSEcCtD
Thalidomide—Insomnia—Paclitaxel—kidney cancer	2.55e-05	0.000153	CcSEcCtD
Thalidomide—Vertigo—Capecitabine—kidney cancer	2.55e-05	0.000153	CcSEcCtD
Thalidomide—Asthenia—Vincristine—kidney cancer	2.55e-05	0.000153	CcSEcCtD
Thalidomide—Syncope—Capecitabine—kidney cancer	2.54e-05	0.000152	CcSEcCtD
Thalidomide—Leukopenia—Capecitabine—kidney cancer	2.54e-05	0.000152	CcSEcCtD
Thalidomide—Paraesthesia—Paclitaxel—kidney cancer	2.53e-05	0.000152	CcSEcCtD
Thalidomide—Vomiting—Dactinomycin—kidney cancer	2.53e-05	0.000152	CcSEcCtD
Thalidomide—Bronchitis—Doxorubicin—kidney cancer	2.52e-05	0.000151	CcSEcCtD
Thalidomide—Dyspnoea—Paclitaxel—kidney cancer	2.52e-05	0.000151	CcSEcCtD
Thalidomide—Somnolence—Paclitaxel—kidney cancer	2.51e-05	0.00015	CcSEcCtD
Thalidomide—Palpitations—Capecitabine—kidney cancer	2.51e-05	0.00015	CcSEcCtD
Thalidomide—Rash—Dactinomycin—kidney cancer	2.51e-05	0.00015	CcSEcCtD
Thalidomide—Nausea—Sunitinib—kidney cancer	2.49e-05	0.00015	CcSEcCtD
Thalidomide—Loss of consciousness—Capecitabine—kidney cancer	2.49e-05	0.000149	CcSEcCtD
Thalidomide—Pancytopenia—Doxorubicin—kidney cancer	2.49e-05	0.000149	CcSEcCtD
Thalidomide—Dyspepsia—Paclitaxel—kidney cancer	2.48e-05	0.000149	CcSEcCtD
Thalidomide—Cough—Capecitabine—kidney cancer	2.48e-05	0.000148	CcSEcCtD
Thalidomide—Neutropenia—Doxorubicin—kidney cancer	2.45e-05	0.000147	CcSEcCtD
Thalidomide—Decreased appetite—Paclitaxel—kidney cancer	2.45e-05	0.000147	CcSEcCtD
Thalidomide—Hypertension—Capecitabine—kidney cancer	2.45e-05	0.000147	CcSEcCtD
Thalidomide—Upper respiratory tract infection—Doxorubicin—kidney cancer	2.44e-05	0.000146	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Paclitaxel—kidney cancer	2.44e-05	0.000146	CcSEcCtD
Thalidomide—Fatigue—Paclitaxel—kidney cancer	2.43e-05	0.000146	CcSEcCtD
Thalidomide—Diarrhoea—Vincristine—kidney cancer	2.43e-05	0.000146	CcSEcCtD
Thalidomide—Pollakiuria—Doxorubicin—kidney cancer	2.42e-05	0.000145	CcSEcCtD
Thalidomide—Asthenia—Gemcitabine—kidney cancer	2.42e-05	0.000145	CcSEcCtD
Thalidomide—Myalgia—Capecitabine—kidney cancer	2.42e-05	0.000145	CcSEcCtD
Thalidomide—Arthralgia—Capecitabine—kidney cancer	2.42e-05	0.000145	CcSEcCtD
Thalidomide—Chest pain—Capecitabine—kidney cancer	2.42e-05	0.000145	CcSEcCtD
Thalidomide—Constipation—Paclitaxel—kidney cancer	2.41e-05	0.000145	CcSEcCtD
Thalidomide—Pain—Paclitaxel—kidney cancer	2.41e-05	0.000145	CcSEcCtD
Thalidomide—Anxiety—Capecitabine—kidney cancer	2.41e-05	0.000144	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	2.4e-05	0.000144	CcSEcCtD
Thalidomide—Photosensitivity reaction—Doxorubicin—kidney cancer	2.4e-05	0.000144	CcSEcCtD
Thalidomide—Weight increased—Doxorubicin—kidney cancer	2.39e-05	0.000143	CcSEcCtD
Thalidomide—Discomfort—Capecitabine—kidney cancer	2.39e-05	0.000143	CcSEcCtD
Thalidomide—Pruritus—Gemcitabine—kidney cancer	2.38e-05	0.000143	CcSEcCtD
Thalidomide—Weight decreased—Doxorubicin—kidney cancer	2.37e-05	0.000142	CcSEcCtD
Thalidomide—Hyperglycaemia—Doxorubicin—kidney cancer	2.37e-05	0.000142	CcSEcCtD
Thalidomide—Dry mouth—Capecitabine—kidney cancer	2.36e-05	0.000142	CcSEcCtD
Thalidomide—Nausea—Dactinomycin—kidney cancer	2.36e-05	0.000142	CcSEcCtD
Thalidomide—Pneumonia—Doxorubicin—kidney cancer	2.35e-05	0.000141	CcSEcCtD
Thalidomide—Dizziness—Vincristine—kidney cancer	2.35e-05	0.000141	CcSEcCtD
Thalidomide—Infestation—Doxorubicin—kidney cancer	2.34e-05	0.00014	CcSEcCtD
Thalidomide—Infestation NOS—Doxorubicin—kidney cancer	2.34e-05	0.00014	CcSEcCtD
Thalidomide—Drowsiness—Doxorubicin—kidney cancer	2.34e-05	0.00014	CcSEcCtD
Thalidomide—Confusional state—Capecitabine—kidney cancer	2.33e-05	0.00014	CcSEcCtD
Thalidomide—Feeling abnormal—Paclitaxel—kidney cancer	2.32e-05	0.000139	CcSEcCtD
Thalidomide—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	2.32e-05	0.000139	CcSEcCtD
Thalidomide—Oedema—Capecitabine—kidney cancer	2.32e-05	0.000139	CcSEcCtD
Thalidomide—Gastrointestinal pain—Paclitaxel—kidney cancer	2.31e-05	0.000138	CcSEcCtD
Thalidomide—Diarrhoea—Gemcitabine—kidney cancer	2.31e-05	0.000138	CcSEcCtD
Thalidomide—Renal failure—Doxorubicin—kidney cancer	2.3e-05	0.000138	CcSEcCtD
Thalidomide—Infection—Capecitabine—kidney cancer	2.3e-05	0.000138	CcSEcCtD
Thalidomide—Neuropathy peripheral—Doxorubicin—kidney cancer	2.29e-05	0.000137	CcSEcCtD
Thalidomide—Stomatitis—Doxorubicin—kidney cancer	2.28e-05	0.000137	CcSEcCtD
Thalidomide—Shock—Capecitabine—kidney cancer	2.28e-05	0.000137	CcSEcCtD
Thalidomide—Conjunctivitis—Doxorubicin—kidney cancer	2.27e-05	0.000136	CcSEcCtD
Thalidomide—Nervous system disorder—Capecitabine—kidney cancer	2.27e-05	0.000136	CcSEcCtD
Thalidomide—Thrombocytopenia—Capecitabine—kidney cancer	2.27e-05	0.000136	CcSEcCtD
Thalidomide—Tachycardia—Capecitabine—kidney cancer	2.26e-05	0.000135	CcSEcCtD
Thalidomide—Vomiting—Vincristine—kidney cancer	2.26e-05	0.000135	CcSEcCtD
Thalidomide—Skin disorder—Capecitabine—kidney cancer	2.25e-05	0.000135	CcSEcCtD
Thalidomide—Sweating—Doxorubicin—kidney cancer	2.24e-05	0.000134	CcSEcCtD
Thalidomide—Urticaria—Paclitaxel—kidney cancer	2.24e-05	0.000134	CcSEcCtD
Thalidomide—Rash—Vincristine—kidney cancer	2.24e-05	0.000134	CcSEcCtD
Thalidomide—Hyperhidrosis—Capecitabine—kidney cancer	2.24e-05	0.000134	CcSEcCtD
Thalidomide—Dermatitis—Vincristine—kidney cancer	2.24e-05	0.000134	CcSEcCtD
Thalidomide—Haematuria—Doxorubicin—kidney cancer	2.23e-05	0.000134	CcSEcCtD
Thalidomide—Abdominal pain—Paclitaxel—kidney cancer	2.23e-05	0.000134	CcSEcCtD
Thalidomide—Body temperature increased—Paclitaxel—kidney cancer	2.23e-05	0.000134	CcSEcCtD
Thalidomide—Headache—Vincristine—kidney cancer	2.23e-05	0.000133	CcSEcCtD
Thalidomide—Epistaxis—Doxorubicin—kidney cancer	2.21e-05	0.000132	CcSEcCtD
Thalidomide—Anorexia—Capecitabine—kidney cancer	2.21e-05	0.000132	CcSEcCtD
Thalidomide—Sinusitis—Doxorubicin—kidney cancer	2.2e-05	0.000132	CcSEcCtD
Thalidomide—Agranulocytosis—Doxorubicin—kidney cancer	2.18e-05	0.000131	CcSEcCtD
Thalidomide—Hypotension—Capecitabine—kidney cancer	2.16e-05	0.00013	CcSEcCtD
Thalidomide—Vomiting—Gemcitabine—kidney cancer	2.14e-05	0.000128	CcSEcCtD
Thalidomide—Bradycardia—Doxorubicin—kidney cancer	2.14e-05	0.000128	CcSEcCtD
Thalidomide—Rash—Gemcitabine—kidney cancer	2.12e-05	0.000127	CcSEcCtD
Thalidomide—Dermatitis—Gemcitabine—kidney cancer	2.12e-05	0.000127	CcSEcCtD
Thalidomide—Headache—Gemcitabine—kidney cancer	2.11e-05	0.000127	CcSEcCtD
Thalidomide—Nausea—Vincristine—kidney cancer	2.11e-05	0.000126	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Capecitabine—kidney cancer	2.11e-05	0.000126	CcSEcCtD
Thalidomide—Rhinitis—Doxorubicin—kidney cancer	2.11e-05	0.000126	CcSEcCtD
Thalidomide—Hepatitis—Doxorubicin—kidney cancer	2.1e-05	0.000126	CcSEcCtD
Thalidomide—Insomnia—Capecitabine—kidney cancer	2.09e-05	0.000126	CcSEcCtD
Thalidomide—Hypoaesthesia—Doxorubicin—kidney cancer	2.09e-05	0.000125	CcSEcCtD
Thalidomide—Pharyngitis—Doxorubicin—kidney cancer	2.08e-05	0.000125	CcSEcCtD
Thalidomide—Paraesthesia—Capecitabine—kidney cancer	2.08e-05	0.000125	CcSEcCtD
Thalidomide—Hypersensitivity—Paclitaxel—kidney cancer	2.08e-05	0.000125	CcSEcCtD
Thalidomide—Urinary tract disorder—Doxorubicin—kidney cancer	2.07e-05	0.000124	CcSEcCtD
Thalidomide—Oedema peripheral—Doxorubicin—kidney cancer	2.07e-05	0.000124	CcSEcCtD
Thalidomide—Dyspnoea—Capecitabine—kidney cancer	2.06e-05	0.000124	CcSEcCtD
Thalidomide—Urethral disorder—Doxorubicin—kidney cancer	2.06e-05	0.000123	CcSEcCtD
Thalidomide—Dyspepsia—Capecitabine—kidney cancer	2.04e-05	0.000122	CcSEcCtD
Thalidomide—Visual impairment—Doxorubicin—kidney cancer	2.02e-05	0.000121	CcSEcCtD
Thalidomide—Asthenia—Paclitaxel—kidney cancer	2.02e-05	0.000121	CcSEcCtD
Thalidomide—Decreased appetite—Capecitabine—kidney cancer	2.01e-05	0.000121	CcSEcCtD
Thalidomide—Nausea—Gemcitabine—kidney cancer	2e-05	0.00012	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Capecitabine—kidney cancer	2e-05	0.00012	CcSEcCtD
Thalidomide—Fatigue—Capecitabine—kidney cancer	2e-05	0.00012	CcSEcCtD
Thalidomide—Pruritus—Paclitaxel—kidney cancer	2e-05	0.00012	CcSEcCtD
Thalidomide—Erythema multiforme—Doxorubicin—kidney cancer	1.99e-05	0.000119	CcSEcCtD
Thalidomide—Pain—Capecitabine—kidney cancer	1.98e-05	0.000119	CcSEcCtD
Thalidomide—Constipation—Capecitabine—kidney cancer	1.98e-05	0.000119	CcSEcCtD
Thalidomide—Eye disorder—Doxorubicin—kidney cancer	1.96e-05	0.000118	CcSEcCtD
Thalidomide—Tinnitus—Doxorubicin—kidney cancer	1.96e-05	0.000117	CcSEcCtD
Thalidomide—Cardiac disorder—Doxorubicin—kidney cancer	1.95e-05	0.000117	CcSEcCtD
Thalidomide—Diarrhoea—Paclitaxel—kidney cancer	1.93e-05	0.000116	CcSEcCtD
Thalidomide—Feeling abnormal—Capecitabine—kidney cancer	1.91e-05	0.000114	CcSEcCtD
Thalidomide—Angiopathy—Doxorubicin—kidney cancer	1.91e-05	0.000114	CcSEcCtD
Thalidomide—Immune system disorder—Doxorubicin—kidney cancer	1.9e-05	0.000114	CcSEcCtD
Thalidomide—Gastrointestinal pain—Capecitabine—kidney cancer	1.89e-05	0.000113	CcSEcCtD
Thalidomide—Mediastinal disorder—Doxorubicin—kidney cancer	1.89e-05	0.000113	CcSEcCtD
Thalidomide—Chills—Doxorubicin—kidney cancer	1.88e-05	0.000113	CcSEcCtD
Thalidomide—Arrhythmia—Doxorubicin—kidney cancer	1.88e-05	0.000112	CcSEcCtD
Thalidomide—Dizziness—Paclitaxel—kidney cancer	1.87e-05	0.000112	CcSEcCtD
Thalidomide—Alopecia—Doxorubicin—kidney cancer	1.86e-05	0.000111	CcSEcCtD
Thalidomide—Mental disorder—Doxorubicin—kidney cancer	1.84e-05	0.00011	CcSEcCtD
Thalidomide—Urticaria—Capecitabine—kidney cancer	1.84e-05	0.00011	CcSEcCtD
Thalidomide—Body temperature increased—Capecitabine—kidney cancer	1.83e-05	0.00011	CcSEcCtD
Thalidomide—Abdominal pain—Capecitabine—kidney cancer	1.83e-05	0.00011	CcSEcCtD
Thalidomide—Malnutrition—Doxorubicin—kidney cancer	1.83e-05	0.00011	CcSEcCtD
Thalidomide—Flatulence—Doxorubicin—kidney cancer	1.8e-05	0.000108	CcSEcCtD
Thalidomide—Tension—Doxorubicin—kidney cancer	1.79e-05	0.000108	CcSEcCtD
Thalidomide—Vomiting—Paclitaxel—kidney cancer	1.79e-05	0.000108	CcSEcCtD
Thalidomide—Dysgeusia—Doxorubicin—kidney cancer	1.79e-05	0.000107	CcSEcCtD
Thalidomide—Rash—Paclitaxel—kidney cancer	1.78e-05	0.000107	CcSEcCtD
Thalidomide—Dermatitis—Paclitaxel—kidney cancer	1.78e-05	0.000107	CcSEcCtD
Thalidomide—Nervousness—Doxorubicin—kidney cancer	1.78e-05	0.000106	CcSEcCtD
Thalidomide—Back pain—Doxorubicin—kidney cancer	1.77e-05	0.000106	CcSEcCtD
Thalidomide—Headache—Paclitaxel—kidney cancer	1.77e-05	0.000106	CcSEcCtD
Thalidomide—Muscle spasms—Doxorubicin—kidney cancer	1.76e-05	0.000105	CcSEcCtD
Thalidomide—Vision blurred—Doxorubicin—kidney cancer	1.72e-05	0.000103	CcSEcCtD
Thalidomide—Hypersensitivity—Capecitabine—kidney cancer	1.71e-05	0.000102	CcSEcCtD
Thalidomide—Ill-defined disorder—Doxorubicin—kidney cancer	1.7e-05	0.000102	CcSEcCtD
Thalidomide—Anaemia—Doxorubicin—kidney cancer	1.69e-05	0.000101	CcSEcCtD
Thalidomide—Agitation—Doxorubicin—kidney cancer	1.68e-05	0.000101	CcSEcCtD
Thalidomide—Nausea—Paclitaxel—kidney cancer	1.68e-05	0.0001	CcSEcCtD
Thalidomide—Asthenia—Capecitabine—kidney cancer	1.66e-05	9.96e-05	CcSEcCtD
Thalidomide—Malaise—Doxorubicin—kidney cancer	1.65e-05	9.88e-05	CcSEcCtD
Thalidomide—Vertigo—Doxorubicin—kidney cancer	1.64e-05	9.85e-05	CcSEcCtD
Thalidomide—Syncope—Doxorubicin—kidney cancer	1.64e-05	9.83e-05	CcSEcCtD
Thalidomide—Pruritus—Capecitabine—kidney cancer	1.64e-05	9.82e-05	CcSEcCtD
Thalidomide—Leukopenia—Doxorubicin—kidney cancer	1.64e-05	9.81e-05	CcSEcCtD
Thalidomide—Palpitations—Doxorubicin—kidney cancer	1.62e-05	9.69e-05	CcSEcCtD
Thalidomide—Loss of consciousness—Doxorubicin—kidney cancer	1.61e-05	9.63e-05	CcSEcCtD
Thalidomide—Cough—Doxorubicin—kidney cancer	1.6e-05	9.56e-05	CcSEcCtD
Thalidomide—Convulsion—Doxorubicin—kidney cancer	1.58e-05	9.5e-05	CcSEcCtD
Thalidomide—Diarrhoea—Capecitabine—kidney cancer	1.58e-05	9.49e-05	CcSEcCtD
Thalidomide—Hypertension—Doxorubicin—kidney cancer	1.58e-05	9.46e-05	CcSEcCtD
Thalidomide—Chest pain—Doxorubicin—kidney cancer	1.56e-05	9.33e-05	CcSEcCtD
Thalidomide—Myalgia—Doxorubicin—kidney cancer	1.56e-05	9.33e-05	CcSEcCtD
Thalidomide—Arthralgia—Doxorubicin—kidney cancer	1.56e-05	9.33e-05	CcSEcCtD
Thalidomide—Anxiety—Doxorubicin—kidney cancer	1.55e-05	9.3e-05	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	1.55e-05	9.27e-05	CcSEcCtD
Thalidomide—Discomfort—Doxorubicin—kidney cancer	1.54e-05	9.22e-05	CcSEcCtD
Thalidomide—Dizziness—Capecitabine—kidney cancer	1.53e-05	9.18e-05	CcSEcCtD
Thalidomide—Dry mouth—Doxorubicin—kidney cancer	1.52e-05	9.13e-05	CcSEcCtD
Thalidomide—Confusional state—Doxorubicin—kidney cancer	1.5e-05	9.02e-05	CcSEcCtD
Thalidomide—Oedema—Doxorubicin—kidney cancer	1.49e-05	8.95e-05	CcSEcCtD
Thalidomide—Infection—Doxorubicin—kidney cancer	1.48e-05	8.89e-05	CcSEcCtD
Thalidomide—Vomiting—Capecitabine—kidney cancer	1.47e-05	8.82e-05	CcSEcCtD
Thalidomide—Shock—Doxorubicin—kidney cancer	1.47e-05	8.8e-05	CcSEcCtD
Thalidomide—Nervous system disorder—Doxorubicin—kidney cancer	1.46e-05	8.77e-05	CcSEcCtD
Thalidomide—Thrombocytopenia—Doxorubicin—kidney cancer	1.46e-05	8.76e-05	CcSEcCtD
Thalidomide—Rash—Capecitabine—kidney cancer	1.46e-05	8.75e-05	CcSEcCtD
Thalidomide—Dermatitis—Capecitabine—kidney cancer	1.46e-05	8.74e-05	CcSEcCtD
Thalidomide—Tachycardia—Doxorubicin—kidney cancer	1.46e-05	8.73e-05	CcSEcCtD
Thalidomide—Headache—Capecitabine—kidney cancer	1.45e-05	8.69e-05	CcSEcCtD
Thalidomide—Skin disorder—Doxorubicin—kidney cancer	1.45e-05	8.69e-05	CcSEcCtD
Thalidomide—Hyperhidrosis—Doxorubicin—kidney cancer	1.44e-05	8.65e-05	CcSEcCtD
Thalidomide—Anorexia—Doxorubicin—kidney cancer	1.42e-05	8.53e-05	CcSEcCtD
Thalidomide—Hypotension—Doxorubicin—kidney cancer	1.39e-05	8.36e-05	CcSEcCtD
Thalidomide—Nausea—Capecitabine—kidney cancer	1.38e-05	8.24e-05	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Doxorubicin—kidney cancer	1.36e-05	8.15e-05	CcSEcCtD
Thalidomide—Insomnia—Doxorubicin—kidney cancer	1.35e-05	8.09e-05	CcSEcCtD
Thalidomide—Paraesthesia—Doxorubicin—kidney cancer	1.34e-05	8.03e-05	CcSEcCtD
Thalidomide—Dyspnoea—Doxorubicin—kidney cancer	1.33e-05	7.98e-05	CcSEcCtD
Thalidomide—Somnolence—Doxorubicin—kidney cancer	1.33e-05	7.95e-05	CcSEcCtD
Thalidomide—Dyspepsia—Doxorubicin—kidney cancer	1.31e-05	7.87e-05	CcSEcCtD
Thalidomide—Decreased appetite—Doxorubicin—kidney cancer	1.3e-05	7.78e-05	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Doxorubicin—kidney cancer	1.29e-05	7.72e-05	CcSEcCtD
Thalidomide—Fatigue—Doxorubicin—kidney cancer	1.29e-05	7.71e-05	CcSEcCtD
Thalidomide—Pain—Doxorubicin—kidney cancer	1.28e-05	7.65e-05	CcSEcCtD
Thalidomide—Constipation—Doxorubicin—kidney cancer	1.28e-05	7.65e-05	CcSEcCtD
Thalidomide—Feeling abnormal—Doxorubicin—kidney cancer	1.23e-05	7.37e-05	CcSEcCtD
Thalidomide—Gastrointestinal pain—Doxorubicin—kidney cancer	1.22e-05	7.31e-05	CcSEcCtD
Thalidomide—Urticaria—Doxorubicin—kidney cancer	1.19e-05	7.11e-05	CcSEcCtD
Thalidomide—Body temperature increased—Doxorubicin—kidney cancer	1.18e-05	7.07e-05	CcSEcCtD
Thalidomide—Abdominal pain—Doxorubicin—kidney cancer	1.18e-05	7.07e-05	CcSEcCtD
Thalidomide—Hypersensitivity—Doxorubicin—kidney cancer	1.1e-05	6.59e-05	CcSEcCtD
Thalidomide—Asthenia—Doxorubicin—kidney cancer	1.07e-05	6.42e-05	CcSEcCtD
Thalidomide—Pruritus—Doxorubicin—kidney cancer	1.06e-05	6.33e-05	CcSEcCtD
Thalidomide—Diarrhoea—Doxorubicin—kidney cancer	1.02e-05	6.12e-05	CcSEcCtD
Thalidomide—Dizziness—Doxorubicin—kidney cancer	9.87e-06	5.92e-05	CcSEcCtD
Thalidomide—Vomiting—Doxorubicin—kidney cancer	9.49e-06	5.69e-05	CcSEcCtD
Thalidomide—Rash—Doxorubicin—kidney cancer	9.41e-06	5.64e-05	CcSEcCtD
Thalidomide—Dermatitis—Doxorubicin—kidney cancer	9.4e-06	5.63e-05	CcSEcCtD
Thalidomide—Headache—Doxorubicin—kidney cancer	9.35e-06	5.6e-05	CcSEcCtD
Thalidomide—Nausea—Doxorubicin—kidney cancer	8.86e-06	5.31e-05	CcSEcCtD
Thalidomide—FGFR2—Immune System—ERBB2—kidney cancer	4.96e-06	5.12e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HIF1A—kidney cancer	4.94e-06	5.1e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TSC2—kidney cancer	4.92e-06	5.09e-05	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—PIK3CA—kidney cancer	4.91e-06	5.08e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—SCARB1—kidney cancer	4.9e-06	5.07e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—MTOR—kidney cancer	4.89e-06	5.05e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD4—kidney cancer	4.88e-06	5.04e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GSTT1—kidney cancer	4.88e-06	5.04e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ACHE—kidney cancer	4.88e-06	5.04e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GSTT1—kidney cancer	4.87e-06	5.03e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ACHE—kidney cancer	4.87e-06	5.03e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PTGS1—kidney cancer	4.86e-06	5.02e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CDKN1B—kidney cancer	4.84e-06	5e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PGK1—kidney cancer	4.78e-06	4.94e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SLC5A3—kidney cancer	4.78e-06	4.94e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PSMD7—kidney cancer	4.76e-06	4.92e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CA9—kidney cancer	4.76e-06	4.92e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL2—kidney cancer	4.73e-06	4.89e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—KDR—kidney cancer	4.72e-06	4.88e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—LDHB—kidney cancer	4.69e-06	4.85e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HIF1A—kidney cancer	4.68e-06	4.84e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TSC2—kidney cancer	4.67e-06	4.83e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	4.65e-06	4.81e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—POMC—kidney cancer	4.65e-06	4.8e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—RAF1—kidney cancer	4.62e-06	4.78e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—SCARB1—kidney cancer	4.62e-06	4.77e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—SCARB1—kidney cancer	4.61e-06	4.76e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—JUN—kidney cancer	4.6e-06	4.76e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ACHE—kidney cancer	4.6e-06	4.75e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GSTT1—kidney cancer	4.6e-06	4.75e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	4.59e-06	4.74e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CDKN1B—kidney cancer	4.59e-06	4.74e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—ERBB2—kidney cancer	4.58e-06	4.73e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTGS1—kidney cancer	4.57e-06	4.72e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CTNNB1—kidney cancer	4.57e-06	4.72e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTGS1—kidney cancer	4.56e-06	4.71e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GSTP1—kidney cancer	4.52e-06	4.68e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MTOR—kidney cancer	4.52e-06	4.67e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—BCHE—kidney cancer	4.51e-06	4.66e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CD4—kidney cancer	4.51e-06	4.66e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL2—kidney cancer	4.49e-06	4.64e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PSMD7—kidney cancer	4.48e-06	4.63e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—KDR—kidney cancer	4.48e-06	4.63e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PTGS2—kidney cancer	4.47e-06	4.62e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PSMD7—kidney cancer	4.47e-06	4.62e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—SLC5A5—kidney cancer	4.46e-06	4.61e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—PTEN—kidney cancer	4.45e-06	4.6e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CRABP1—kidney cancer	4.44e-06	4.59e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—JUN—kidney cancer	4.37e-06	4.52e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—SCARB1—kidney cancer	4.35e-06	4.5e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—KIT—kidney cancer	4.35e-06	4.49e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—APC—kidney cancer	4.35e-06	4.49e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CTNNB1—kidney cancer	4.34e-06	4.48e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTGS1—kidney cancer	4.31e-06	4.45e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—SLC2A1—kidney cancer	4.31e-06	4.45e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ABCB1—kidney cancer	4.28e-06	4.43e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—BCHE—kidney cancer	4.25e-06	4.39e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—BCHE—kidney cancer	4.24e-06	4.38e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CDKN1B—kidney cancer	4.24e-06	4.38e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PSMD7—kidney cancer	4.23e-06	4.37e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—PTEN—kidney cancer	4.23e-06	4.37e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—SLC5A5—kidney cancer	4.2e-06	4.34e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—SLC5A5—kidney cancer	4.19e-06	4.33e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GSTM1—kidney cancer	4.16e-06	4.3e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CDKN2B—kidney cancer	4.15e-06	4.29e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—POMC—kidney cancer	4.14e-06	4.28e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ITPR2—kidney cancer	4.13e-06	4.26e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—APC—kidney cancer	4.13e-06	4.26e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—KIT—kidney cancer	4.13e-06	4.26e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—BRAF—kidney cancer	4.09e-06	4.22e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CA9—kidney cancer	4.07e-06	4.2e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—SLC2A1—kidney cancer	4.05e-06	4.19e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CRABP1—kidney cancer	4.05e-06	4.18e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—SLC2A1—kidney cancer	4.05e-06	4.18e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—BCHE—kidney cancer	4.01e-06	4.14e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CTNNB1—kidney cancer	4e-06	4.14e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	3.98e-06	4.11e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—SLC5A5—kidney cancer	3.96e-06	4.09e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CYP1A1—kidney cancer	3.94e-06	4.07e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—POMC—kidney cancer	3.93e-06	4.06e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PTEN—kidney cancer	3.9e-06	4.03e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—BRAF—kidney cancer	3.88e-06	4.01e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—SLC2A1—kidney cancer	3.82e-06	3.95e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—MAPK3—kidney cancer	3.81e-06	3.93e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—POMC—kidney cancer	3.8e-06	3.93e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ACHE—kidney cancer	3.76e-06	3.89e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GSTT1—kidney cancer	3.76e-06	3.89e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ITPR2—kidney cancer	3.76e-06	3.89e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	3.71e-06	3.83e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	3.64e-06	3.77e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—MAPK1—kidney cancer	3.62e-06	3.74e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—MAPK3—kidney cancer	3.61e-06	3.73e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GSTP1—kidney cancer	3.59e-06	3.71e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—SCARB1—kidney cancer	3.56e-06	3.68e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTGS1—kidney cancer	3.53e-06	3.64e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—kidney cancer	3.47e-06	3.58e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CRABP1—kidney cancer	3.46e-06	3.57e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PSMD7—kidney cancer	3.46e-06	3.57e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—MAPK1—kidney cancer	3.44e-06	3.55e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GSTT1—kidney cancer	3.43e-06	3.55e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ACHE—kidney cancer	3.43e-06	3.55e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—KRAS—kidney cancer	3.42e-06	3.53e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—RAF1—kidney cancer	3.41e-06	3.53e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ABCB1—kidney cancer	3.4e-06	3.51e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—RELA—kidney cancer	3.4e-06	3.51e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GSTP1—kidney cancer	3.38e-06	3.49e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ERBB2—kidney cancer	3.38e-06	3.49e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GSTP1—kidney cancer	3.37e-06	3.49e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MAPK3—kidney cancer	3.33e-06	3.45e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MTOR—kidney cancer	3.33e-06	3.44e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HIF1A—kidney cancer	3.32e-06	3.43e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TSC2—kidney cancer	3.31e-06	3.42e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GSTM1—kidney cancer	3.3e-06	3.41e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—BCHE—kidney cancer	3.28e-06	3.39e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SCARB1—kidney cancer	3.25e-06	3.36e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—KRAS—kidney cancer	3.24e-06	3.35e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MYC—kidney cancer	3.24e-06	3.35e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—RAF1—kidney cancer	3.24e-06	3.35e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—SLC5A5—kidney cancer	3.24e-06	3.35e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.24e-06	3.35e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	3.23e-06	3.34e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—RELA—kidney cancer	3.22e-06	3.33e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ITPR2—kidney cancer	3.22e-06	3.32e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTGS1—kidney cancer	3.22e-06	3.32e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ERBB2—kidney cancer	3.2e-06	3.31e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ABCB1—kidney cancer	3.2e-06	3.31e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ABCB1—kidney cancer	3.19e-06	3.3e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GSTP1—kidney cancer	3.19e-06	3.29e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MAPK1—kidney cancer	3.17e-06	3.28e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MTOR—kidney cancer	3.16e-06	3.27e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PSMD7—kidney cancer	3.15e-06	3.26e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—PIK3CA—kidney cancer	3.14e-06	3.25e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CYP1A1—kidney cancer	3.13e-06	3.23e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—SLC2A1—kidney cancer	3.13e-06	3.23e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CDKN1B—kidney cancer	3.13e-06	3.23e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GSTM1—kidney cancer	3.11e-06	3.21e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GSTM1—kidney cancer	3.1e-06	3.2e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL2—kidney cancer	3.06e-06	3.16e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	3.03e-06	3.14e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ABCB1—kidney cancer	3.02e-06	3.12e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—KRAS—kidney cancer	3e-06	3.1e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—BCHE—kidney cancer	2.99e-06	3.09e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCND1—kidney cancer	2.98e-06	3.08e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—PIK3CA—kidney cancer	2.98e-06	3.08e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—JUN—kidney cancer	2.98e-06	3.08e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CDKN1B—kidney cancer	2.97e-06	3.07e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	2.96e-06	3.06e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CTNNB1—kidney cancer	2.95e-06	3.05e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SLC5A5—kidney cancer	2.95e-06	3.05e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CYP1A1—kidney cancer	2.95e-06	3.04e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP1A1—kidney cancer	2.94e-06	3.04e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—POMC—kidney cancer	2.94e-06	3.04e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTT1—kidney cancer	2.93e-06	3.03e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ACHE—kidney cancer	2.93e-06	3.03e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GSTM1—kidney cancer	2.93e-06	3.03e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—KIT—kidney cancer	2.93e-06	3.02e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APC—kidney cancer	2.93e-06	3.02e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL2—kidney cancer	2.9e-06	3e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PTEN—kidney cancer	2.88e-06	2.98e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SLC2A1—kidney cancer	2.85e-06	2.95e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCND1—kidney cancer	2.83e-06	2.93e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—JUN—kidney cancer	2.82e-06	2.92e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CTNNB1—kidney cancer	2.8e-06	2.9e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SCARB1—kidney cancer	2.78e-06	2.87e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	2.77e-06	2.86e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PIK3CA—kidney cancer	2.75e-06	2.84e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—BRAF—kidney cancer	2.75e-06	2.84e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTGS1—kidney cancer	2.75e-06	2.84e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PTEN—kidney cancer	2.73e-06	2.82e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PSMD7—kidney cancer	2.69e-06	2.78e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	2.65e-06	2.73e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GSTP1—kidney cancer	2.61e-06	2.7e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—VEGFA—kidney cancer	2.6e-06	2.69e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.57e-06	2.66e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—BCHE—kidney cancer	2.55e-06	2.64e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SLC5A5—kidney cancer	2.52e-06	2.61e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ABCB1—kidney cancer	2.47e-06	2.55e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—VEGFA—kidney cancer	2.47e-06	2.55e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MAPK3—kidney cancer	2.46e-06	2.54e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SLC2A1—kidney cancer	2.44e-06	2.52e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	2.41e-06	2.49e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GSTM1—kidney cancer	2.4e-06	2.48e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MYC—kidney cancer	2.39e-06	2.47e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GSTP1—kidney cancer	2.38e-06	2.46e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	2.36e-06	2.44e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTGS2—kidney cancer	2.34e-06	2.42e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MAPK1—kidney cancer	2.34e-06	2.42e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MAPK3—kidney cancer	2.33e-06	2.41e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—POMC—kidney cancer	2.33e-06	2.41e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—RAF1—kidney cancer	2.3e-06	2.37e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.28e-06	2.36e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP1A1—kidney cancer	2.27e-06	2.35e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ERBB2—kidney cancer	2.27e-06	2.35e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MYC—kidney cancer	2.27e-06	2.35e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ABCB1—kidney cancer	2.25e-06	2.33e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MTOR—kidney cancer	2.24e-06	2.32e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CD4—kidney cancer	2.24e-06	2.31e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MAPK1—kidney cancer	2.22e-06	2.3e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—KRAS—kidney cancer	2.21e-06	2.29e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—POMC—kidney cancer	2.2e-06	2.27e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—POMC—kidney cancer	2.19e-06	2.26e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GSTM1—kidney cancer	2.19e-06	2.26e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CDKN1B—kidney cancer	2.1e-06	2.17e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—KRAS—kidney cancer	2.1e-06	2.17e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP1A1—kidney cancer	2.07e-06	2.14e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—POMC—kidney cancer	2.07e-06	2.14e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	2.06e-06	2.13e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTEN—kidney cancer	2.04e-06	2.11e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTP1—kidney cancer	2.03e-06	2.1e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PIK3CA—kidney cancer	2.03e-06	2.1e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CTNNB1—kidney cancer	1.99e-06	2.05e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TP53—kidney cancer	1.97e-06	2.03e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PTEN—kidney cancer	1.94e-06	2e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PIK3CA—kidney cancer	1.93e-06	1.99e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ABCB1—kidney cancer	1.92e-06	1.99e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTM1—kidney cancer	1.87e-06	1.93e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.87e-06	1.93e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TP53—kidney cancer	1.86e-06	1.93e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP1A1—kidney cancer	1.77e-06	1.83e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTGS2—kidney cancer	1.75e-06	1.81e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTGS2—kidney cancer	1.75e-06	1.81e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.7e-06	1.76e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—POMC—kidney cancer	1.69e-06	1.75e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MAPK3—kidney cancer	1.66e-06	1.71e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTGS2—kidney cancer	1.65e-06	1.71e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PTEN—kidney cancer	1.62e-06	1.68e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MYC—kidney cancer	1.61e-06	1.66e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MAPK1—kidney cancer	1.58e-06	1.63e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—POMC—kidney cancer	1.54e-06	1.6e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTEN—kidney cancer	1.53e-06	1.58e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTEN—kidney cancer	1.52e-06	1.58e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—KRAS—kidney cancer	1.49e-06	1.54e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.45e-06	1.5e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3CA—kidney cancer	1.44e-06	1.49e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTEN—kidney cancer	1.44e-06	1.49e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PIK3CA—kidney cancer	1.37e-06	1.41e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTGS2—kidney cancer	1.35e-06	1.4e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—POMC—kidney cancer	1.32e-06	1.36e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTGS2—kidney cancer	1.23e-06	1.27e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTEN—kidney cancer	1.18e-06	1.22e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CA—kidney cancer	1.14e-06	1.18e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CA—kidney cancer	1.08e-06	1.11e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CA—kidney cancer	1.08e-06	1.11e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTEN—kidney cancer	1.07e-06	1.11e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTGS2—kidney cancer	1.05e-06	1.09e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CA—kidney cancer	1.02e-06	1.05e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTEN—kidney cancer	9.18e-07	9.49e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CA—kidney cancer	8.31e-07	8.59e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CA—kidney cancer	7.58e-07	7.83e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CA—kidney cancer	6.48e-07	6.69e-06	CbGpPWpGaD
